SequelSEC

Damora Therapeutics, Inc. DMRA

Pharmaceutical Preparations · CIK 0001800315 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
Unavailable
Fiscal year ended 2025-12-31
Operating income
-$210.87M
Fiscal year ended 2025-12-31
Free cash flow
Unavailable
Fiscal year ended 2025-12-31

Damora Therapeutics, Inc. (DMRA) reported net income of -$209.84M for the fiscal year ended 2025-12-31. This page shows 7 annual periods of income statement, balance sheet and cash flow figures normalized from Damora Therapeutics, Inc.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Pharmaceutical Preparations.

Income

Damora Therapeutics, Inc. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-31
RevenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Cost of revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Gross profitUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Operating income-$210.87M-$22.26M-$39.90M-$61.21M-$52.23M-$33.64M$38.97M
Net income-$209.84M-$21.44M-$38.35M-$61.62M-$51.75M-$34.84M-$36.51M
Research & development$26.88M$6.40M$23.77M$48.21M$38.49M$24.63M$19.74M
Weighted-average diluted sharesshares 1.36Mshares 1.16Mshares 1.06Mshares 25.41Mshares 25.26MUnavailableUnavailable
Pretax income-$209.79M-$21.40M-$38.35M-$61.62M-$51.75M-$34.84M-$36.51M
Income tax expense$50.00K$41.00K$0$0$0$0$0
Diluted EPS$3.98$-18.53$-36.08$-2.43$-2.05UnavailableUnavailable
Selling, general & administrativeUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
General & administrative$9.68M$10.50M$12.69M$13.00M$13.74M$9.01M$2.44M
Selling & marketingUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Balance

Damora Therapeutics, Inc. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-31
Cash & equivalents$257.62M$14.18M$21.46M$32.79M$62.56M$163.58M$11.29M
Total assets$260.53M$17.13M$38.23M$73.19M$122.22M$171.60M$56.61M
Current assets$260.42M$16.84M$36.77M$63.91M$110.10M$169.30M$56.08M
Total liabilities$20.15M$1.30M$5.90M$11.44M$4.99M$6.11M$8.14M
Current liabilities$20.07M$1.20M$5.83M$11.11M$4.54M$5.57M$7.93M
Total equity incl. NCI$240.38M$15.83M$32.33M$61.75M$117.22M$165.49M-$71.15M
Temporary (mezzanine) equity$1.34M$1.36MUnavailableUnavailableUnavailableUnavailable$119.62M
InventoryUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Accounts receivableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
GoodwillUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Long-term debtUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Accounts payable$444.00K$377.00K$1.70M$3.35M$1.53M$2.85M$3.33M

Cash flow

Damora Therapeutics, Inc. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-31
Operating cash flow-$6.73M-$18.62M-$36.91M-$42.93M-$52.31M-$38.20M-$19.33M
Capital expendituresUnavailableUnavailableUnavailable$196.00K$223.00KUnavailableUnavailable
Investing cash flow-$17.37M$11.65M$22.33M$12.38M-$48.05MUnavailable-$326.00K
Financing cash flow$266.84MUnavailable$2.88M$507.00KUnavailable$187.39MUnavailable
Net change in cashUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Stock-based compensation$998.00K$3.24M$5.43M$5.57M$4.48M$982.00KUnavailable
Common dividends paidUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Common share repurchasesUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Depreciation & amortizationUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Derived

Damora Therapeutics, Inc. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-31
Free cash flowUnavailableUnavailableUnavailable-$43.13M-$52.53MUnavailableUnavailable
Gross marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Operating marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
FCF marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
SBC / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Current ratio12.98x14.07x6.31x5.75x24.23x30.42x7.07x
Revenue YoY growthUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Net marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
R&D / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
CapEx / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Long-term debt / equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Effective tax rateUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open DMRA in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-10View SEC filing
10-Q · Filed 2026-05-12View SEC filing
10-K · Filed 2026-03-19View SEC filing
10-Q · Filed 2025-11-06View SEC filing
10-Q · Filed 2025-08-05View SEC filing
10-Q · Filed 2025-05-08View SEC filing

Companies in the same industry

AAGH AARD ABBV ABCL ABEO ABT ABUS ABVC ACAD ACET ACRS ACRV

Reconciliation checks needing review

2 periods on this page do not reconcile under this site’s normalization. Read that as a limitation here before an observation about the company: the figures are the filer’s own, the filings linked above are authoritative, and a difference usually means the concepts this site selected do not match how this filer presents its statements. Nothing is adjusted to make a check pass.

balance equationreview2025-12-31

Difference 1341000 exceeds tolerance 1000000. Presentation or filing-vintage differences need review.

balance equationreview2024-12-31

Difference 1360000 exceeds tolerance 1000000. Presentation or filing-vintage differences need review.